Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $119.00

Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $119.00.

A number of equities analysts have commented on the company. Truist Financial lowered their price objective on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Mizuho upped their price objective on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. SVB Leerink raised their target price on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $101.22 on Friday. Lantheus has a one year low of $50.20 and a one year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.55. The firm has a market cap of $7.02 billion, a price-to-earnings ratio of 15.45 and a beta of 0.51. The stock’s fifty day moving average price is $96.48 and its two-hundred day moving average price is $77.24.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million during the quarter, compared to analyst estimates of $382.12 million. During the same quarter last year, the firm earned $1.40 EPS. Lantheus’s revenue for the quarter was up 22.5% compared to the same quarter last year. On average, equities analysts forecast that Lantheus will post 6.46 EPS for the current year.

Insider Buying and Selling at Lantheus

In other news, Director Heinz Christoph Maeusli sold 18,373 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the completion of the transaction, the director now directly owns 23,340 shares in the company, valued at $1,848,294.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The disclosure for this sale can be found here. Insiders have sold 72,439 shares of company stock worth $6,432,198 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Institutional investors have recently modified their holdings of the business. Quarry LP lifted its holdings in Lantheus by 51.3% during the 2nd quarter. Quarry LP now owns 1,145 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 388 shares during the period. Creative Planning lifted its stake in shares of Lantheus by 48.5% in the second quarter. Creative Planning now owns 23,714 shares of the medical equipment provider’s stock worth $1,904,000 after acquiring an additional 7,742 shares during the period. Mackenzie Financial Corp boosted its holdings in Lantheus by 259.2% in the second quarter. Mackenzie Financial Corp now owns 15,571 shares of the medical equipment provider’s stock valued at $1,250,000 after acquiring an additional 11,236 shares during the last quarter. Diker Management LLC acquired a new stake in Lantheus during the 2nd quarter valued at approximately $419,000. Finally, Alpha DNA Investment Management LLC bought a new position in Lantheus during the 2nd quarter worth approximately $412,000. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.